PPT-OBV/PTV/r DSV Open label

18 years Chronic HCV infection Genotype 1 Treatment naïve or PEGIFN RBV experienced HCV RNA gt 1000 IUml Chronic kidney disease with eGFR MDRD lt 30 mlmin173m 2 dialysis permitted. brPage 2br Tough jobsitetested labels for industrial applications Rely on DYMO Industrial Labels DYMO Industrial labels are tough jobsite tested and UL recognized Thermal transfer printing means labels wont smudge smear or fade Choose up to a 24 mm 1 716 60 382 16 73 18 18 20 25 D4110 98 91 58 10 45 14 29 D4111 47 279 241 170 22 92 12 32 D4112 315 851 213 428 121 276 37 80 D4117 947 2358 1105 1357 647 823 95 493 86 86 D4124 283 494 152 358 173 499 296 3471 35 35 D4125 381 754 74 304 17 140 83 O PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV . + RBV. 2-steps. Randomisation*. Open-label. W12. W8. W24. 18-70 years. Chronic HCV infection . Genotype 1. HCV RNA ≥ 50,000 IU/ml. Treatment-naïve . Xers. . in the Field. TRAC Dev Workshop . January 2012. 1. Generation Definition. 2. Live Births and Fertility Rate. 3. Boomer Influences. 4. Gen X Influences: ‘80-00. Columbia & Challenger, Berlin Wall, AIDS, . *. 1:1. Open-label. ≥ 18 years. HCV genotype 4. HCV RNA ≥ 1 000 IU/mL. Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis ** . No HBV or HIV co-infection. N = 59. W12. OPV/PTV/r + RBV. Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). NEED FOR FURTHER RESEARCH. PATRICIA M KHU, MD,MS. UNIVERSITY OF THE PHILIPPINES MANILA . RESEARCH ETHICS BOARD (UPMREB). CARDINAL SANTOS MEDICAL CENTER . RESEARCH ETHICS REVIEW COMMITTEE (CSMC-RERC). N = 100. W12. W24. Arm B: . compensated cirrhosis. N = 31. N = 29. Arm C:. compensated cirrhosis. Arm A: . No cirrhosis. AGATE-II Study: OBV/PTV/r + RBV in genotype 4 Egyptian patients without or with cirrhosis . OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open label. 18-70 years. Chronic HCV infection. Genotype 4 . Treatment-naïve or failure . t. o PEG-IFN + RBV. HCV RNA > 10,000 IU/ml. No cirrhosis**. No HBV or HIV co-infection. Switching. ). Christophe . Fillot. . DSI. 2. . Rappels sur le routage IP. Intérêt de MPLS. . 3. . Routage des paquets IP. Le routeur reçoit un paquet IP sur une de ses interfaces,. Il extrait l ’adresse IP de destination présente dans le paquet,. Journey Maps. Customer . Profile. Building Killer . Products. “. Be grateful for whoever comes because . each . has been sent as a guide from beyond.. ” . ~ Rumi. Salman Azhar @ DSV 2017. Killer Products - . NOT. regulated by EU legislation and no uniform definition is available.. Off-label use of a medicine is the use of an authorised medicine by a healthcare professional to treat a patient in a way not covered by Marketing Authorisation (MA) and detailed in the Summary of Product Characteristics (. IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . What are V20 and V5 and how do we reduce dose to normal lung? Dr Anusheel Munshi Senior Consultant, Radiation Oncology, Fortis Memorial Research Institute, Gurgaon anusheel.munshi@fortishealthcare.com